Costantino Sgamato

Dr. Costantino Sgamato

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2017 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
DCDebora Compare
Debora Compare
ARAlba Rocco
Alba Rocco
PCPietro Coccoli
Pietro Coccoli
DADebora Angrisani
Debora Angrisani
CSCostantino Sgamato
Costantino Sgamato
GNGerardo Nardone
Gerardo Nardone
The evidence on the role of gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing. Lactobacillus spp. positively affect IBS symptoms, although the mechanisms through which probiotics exert their beneficial effects are largely unknown. The aim of the study is to evaluate the role of Lactobacillus casei DG (LC-DG) and its postbiotic (PB) in modulating the inflammatory/immune-response in PI-IBS in an ex-vivo organ culture model. Ex vivo cultures of ileal and colonic mucosa from 10 PI-IBS, diarrhea predominant subtype (D) patients, and 10 healthy controls (HC) were treated with LPS, LC-DG and PB. Interleukin (IL)-1α, IL-6, IL-8 and IL-10 mRNA levels were assessed by real-time PCR and Toll like receptor 4 (TLR-4) protein expression by Western blotting. At baseline, IL-1α, IL-6 and IL-8 mRNA levels as well as TLR-4 protein expression were significantly higher while IL-10 mRNA levels were lower in PI-IBS D than in HC in both ileum and colon. LC-DG and PB significantly reduced the mRNA levels of pro-inflammatory cytokines and TLR-4 while increased that of IL-10 after LPS stimulation. The protective effect was more pronounced for PB than LC-DG treatment. LC-DG and its PB attenuate the inflammatory mucosal response in an ex-vivo organ culture model of PI-IBS D.

1 September 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
ARAlba Rocco
Alba Rocco
CSCostantino Sgamato
Costantino Sgamato
DCDebora Compare
Debora Compare
GNGerardo Nardone
Gerardo Nardone

24 May 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
CSCostantino Sgamato
Costantino Sgamato
ARAlba Rocco
Alba Rocco
DCDebora Compare
Debora Compare
KPKateryna Priadko
Kateryna Priadko
MRMarco Romano
Marco Romano
GNGerardo Nardone
Gerardo Nardone
Gastric cancer (GC) still represents one of the leading causes of cancer-related mortality and is a major public health issue worldwide. Understanding the etiopathogenetic mechanisms behind GC development holds immense potential to revolutionize patients’ treatment and prognosis. Within the complex web of genetic predispositions and environmental factors, the connection between Helicobacter pylori (H. pylori) and gastric microbiota emerges as a focus of intense research investigation. According to the most recent hypotheses, H. pylori triggers inflammatory responses and molecular alterations in gastric mucosa, while non-Helicobacter microbiota modulates disease progression. In this review, we analyze the current state of the literature on the relationship between H. pylori and non-Helicobacter gastric microbiota in gastric carcinogenesis, highlighting the mechanisms by which microecological dysbiosis can contribute to the malignant transformation of the mucosa.

14 July 2024 in Digestive and Liver Disease
Verified
Journal Article
Closed access
MCMarilia Carabotti
Marilia Carabotti
CSCostantino Sgamato
Costantino Sgamato
AAAntonio Amato
Antonio Amato
BBBenedetta Beltrame
Benedetta Beltrame
GBGian Andrea Binda
Gian Andrea Binda
RCRosario Cuomo
Rosario Cuomo

12 January 2026 in Livers
Verified
Journal Article
Open access
PDF file
CSCostantino Sgamato
Costantino Sgamato
SMStefano Andrea Marchitto
Stefano Andrea Marchitto
DCDebora Compare
Debora Compare
PCPietro Coccoli
Pietro Coccoli
VCVincenzo Colace
Vincenzo Colace
ARAlba Rocco
Alba Rocco
Background/Objectives: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer and cancer-related death worldwide. Beyond the well-known factors influencing the risk of HCC, experimental data from animal models and observational human studies support a significant role of the gut microbiota (GM) in HCC initiation and progression. Dysbiosis and increased intestinal permeability synergistically disrupt the ‘gut–liver axis,’ exposing the liver to bacterial metabolites and microbial-associated molecular patterns, thereby contributing to hepatocarcinogenesis. While these findings have expanded our understanding of HCC pathogenesis, a critical translational gap persists as most data derive from preclinical settings, with limited validation in large-scale clinical studies. Methods: This narrative review aimed to contextualise the current evidence on the GM-HCC axis and its clinical translatability. A literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science up to July 2025 using Medical Subject Headings and related keywords, including HCC, GM, dysbiosis, intestinal permeability, gut–liver axis, microbial metabolites, inflammation/immune modulation, and microbiota-targeted interventions (probiotics, antibiotics, and faecal microbiota transplantation). Reference lists of relevant articles were also screened to identify additional studies. Results: Preclinical models consistently indicate that dysbiosis and impaired gut barrier function can promote hepatic inflammation, immune dysregulation, and pro-tumorigenic signalling through microbe-derived products and metabolite perturbations, supporting a contributory role of the GM in hepatocarcinogenesis. In humans, HCC and advanced chronic liver disease are associated with altered microbial composition and function, increased markers of intestinal permeability, and changes in bile acid and other metabolite profiles; however, reported signatures are heterogeneous across cohorts and analytical platforms. Conclusions: The GM is a biologically plausible and experimentally supported contributor to HCC initiation and progression, with potential for biomarker development and therapeutic targeting. However, clinical translation is limited by predominantly preclinical/associative evidence, interindividual variability, and non-standardised microbiome methods. Large longitudinal studies and adequately powered randomised trials are needed to establish causality, validate biomarkers, and determine whether GM modulation improves HCC prevention, detection, stratification, or outcomes.

5 October 2026 in Crohn’s & Colitis 360
Verified
Journal Article
Open access
CSCostantino Sgamato
Costantino Sgamato
CACarmen Ambrosio
Carmen Ambrosio
SMStefano Minieri
Stefano Minieri
GZGiovanni Zerella
Giovanni Zerella
ARAlba Rocco
Alba Rocco
DCDebora Compare
Debora Compare
Background: Emerging evidence links inflammatory bowel disease (IBD) to neurological and mood disorders, but cognitive function in this population remains understudied. By using Montreal Cognitive Assessment (MoCA) we screened for mild cognitive impairment (MCI) patients with IBD and healthy controls (HC). Methods: We enrolled a highly selected cohort of 120 patients with IBD in clinical, biochemical, and endoscopic remission (59 with ulcerative colitis [UC] and 61 with Crohn’s disease [CD]) and 115 matched HC. A MoCA score <26 was considered a below-threshold cognitive screening result, not a clinical diagnosis of mild cognitive impairment. The Hospital Anxiety and Depression Scale (HADS) was used to assess current symptoms rather than establish psychiatric diagnoses. Results: MoCA scores <26 were more frequent among patients with IBD than HC (57% vs. 42%, P = .016), even after excluding participants with HADS scores in the probable-symptom range (57.9% vs. 37.5%, P = .009). Mean total MoCA scores did not differ significantly between groups (25.0 vs. 25.3, P = .280). In exploratory subgroup comparisons, patients with UC had lower naming-domain scores than HC (P = .002). In multivariable analysis, age (odds ratio [OR] 1.03, 95% confidence interval [CI] 1.0–1.1; P = .002), IBD diagnosis (OR 3.07, 95% CI 1.4–6.4; P = .003), and years of schooling (OR 0.85, 95% CI 0.7–1.0; P = .030) were independently associated with a MoCA score <26. After excluding participants with HADS scores in the probable-symptom range, IBD diagnosis (OR 2.72, 95% CI 1.1–6.5; P = .025) and years of schooling (OR 0.71, 95% CI 0.6–0.9; P = .001) remained associated with a below-threshold score. Conclusions: In this highly selected sample, IBD was associated with a greater proportion of below-threshold MoCA scores. These findings reflect cognitive performance and do not establish a higher prevalence of cognitive impairment, a causal mechanism, or a rationale for universal screening. Longitudinal studies incorporating diagnostic neuropsychological assessment are needed.